Biosimilar switching: is there a nocebo effect that contributes to treatment failure?
By Mardi Chapman
10 Feb 2020
More research is required to explore whether the nocebo effect on biosimilar switching may contribute to biologic treatment failure, clinicians say. In a review article of non-medical biosimilar switching the nocebo effect was defined as disease worsening or occurrence of a new or worsening adverse event resulting from a patient’s negative expectations toward a new ...